Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc (NYSE: SNN, LSE: SN) is a global medical technology business whose news flow reflects activity across orthopaedics, sports medicine & ENT, and advanced wound management. Company announcements frequently highlight new product launches, clinical evidence, strategic partnerships and portfolio updates that are relevant to surgeons, healthcare providers and investors following SNN stock.
Recent news has showcased advanced wound management innovations, such as clinical data on the PICO◊ Single Use Negative Pressure Wound Therapy System demonstrating reductions in wound dehiscence, length of stay and costs versus an alternative device in orthopaedic and cardiovascular surgery, and studies on the ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing describing its mechanism in absorbing and dissipating shear forces linked to pressure injury risk.
In Sports Medicine, Smith+Nephew news items have covered the REGENETEN◊ Bioinductive Implant, including randomized controlled trial results and expanded indications to extra-articular ligament injuries, as well as updates on the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, including the establishment of a Category I CPT code recognising its clinical significance and adoption. Announcements also describe launches such as the Q-FIX™ KNOTLESS All-Suture Anchor and the CENTRIO Platelet-Rich-Plasma System for chronic exuding wounds.
Orthopaedics-related releases include the launch of the TRIGEN™ MAX Tibia Nailing System for tibial fractures and the expansion of CORIOGRAPH™ Pre-Op Planning and Modeling Services to total shoulder arthroplasty, alongside references to the AETOS◊ Shoulder System. Strategic and investor-focused news covers topics such as the RISE strategy, medium-term financial targets, and acquisitions like Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology.
Visitors to this SNN news page can review these updates in one place, tracking how Smith & Nephew presents clinical data, regulatory milestones, portfolio expansions, partnerships with organisations such as UFC and Wimbledon, and capital markets communications that shape the company’s profile in the global medical technology sector.
Smith+Nephew (NYSE:SNN) revealed study results at the AOSSM-AANA Combined 2021 Annual Meeting showing its REGENETEN Bioinductive Implant significantly improved early recovery in patients with partial-thickness rotator cuff tears compared to traditional surgical repair. The study, involving 227 patients, found that those treated with the implant alone reported better shoulder function at 2 and 6 weeks post-operation, with equivalent efficacy at one year. The implant is minimally invasive and resorbs within six months, supporting tissue growth and recovery.
Smith+Nephew (NYSE:SNN) has launched the FAST-FIX FLEX Meniscal Repair System, a breakthrough device featuring a surgeon-guided, bendable needle that enhances access to all meniscal zones. This innovation potentially increases repair rates over removal, addressing over 400,000 procedures annually in the U.S. The system boasts a 25% reduction in needle insertion area and stronger repairs. It is designed to improve procedural efficiency and minimize the need for incisions, ultimately aiming to shift the standard of care from meniscectomy to meniscal repair.
Smith+Nephew (NYSE:SNN) has launched ARIA Home PT, a remote physical therapy solution that enhances patient care by providing customized experiences and actionable data. The product significantly reduces healthcare costs, with an average savings of $2,745 per patient, while decreasing readmissions (60%) and outpatient visits (86%). ARIA Home PT leverages advanced technology and telehealth, improving patient adherence by 35% and achieving a Net Promoter Score of 90.3. The launch addresses growing demand for physical therapy amid a projected therapist shortage by 2025.
Smith+Nephew (NYSE:SNN) published research indicating that 45% of clinicians believe their patients with chronic wounds would benefit from more involvement in their care, which can free up time for additional patients. The study, published in Wounds International, highlighted the role of COVID-19 in increasing remote care and patient engagement through digital tools. Despite positive feedback about shared care approaches in regions like the USA and UK, clinicians expressed the need for support in identifying suitable patients for shared care. The research involved 511 healthcare practitioners globally.
Smith+Nephew (LSE: SN, NYSE: SNN) announces a study demonstrating that its computer-guided technology for total hip arthroplasty (THA), known as RI.HIP NAVIGATION, significantly lowers revision rates and enhances patient satisfaction. Utilizing the National Joint Registry of England, Wales, and Northern Ireland, the study found a 55% lower risk of revision at ten years (1.06% vs. 3.88% for conventional THA). Higher patient satisfaction rates were also reported in the computer-guided group. This technology aims to improve long-term outcomes for patients undergoing hip replacement.
Smith+Nephew (NYSE:SNN) announces the launch of DOUBLEFLO Inflow/Outflow Pump and 4KO (Optimized) Arthroscopes and Laparoscopes, enhancing the INTELLIO Connected Tower Solution. The DOUBLEFLO Pump is remotely controllable, allowing surgeons to focus on patients during procedures. The 4KO Scopes promise a 30% increase in image resolution, supporting multi-specialty centers. Both products are now available in the US and Europe, aimed at improving surgical performance and capital investment value.
Smith+Nephew (LSE:SN, NYSE:SNN) announced that its LEAF Patient Monitoring System has monitored over 60,000 patients, accumulating more than 7 million hours of use. This system aims to reduce hospital-acquired pressure injuries (HAPIs), which have risen in the U.S., costing an average of $21,767 per patient. Clinical trials indicated a 73% reduction in HAPI odds, potentially saving up to $39 billion nationally. By implementing the LEAF System, healthcare facilities have raised patient repositioning adherence from under 50% to as high as 98%, enhancing patient care and reducing costs.
Smith+Nephew (LSE:SN, NYSE:SNN) has announced a marketing collaboration with Movendo Technology to enhance its Real Intelligence ecosystem with personalized robotic rehabilitation capabilities. This collaboration, initiated in Europe, focuses on Movendo's HUNOVA rehabilitation device, which analyzes biomechanics to create individualized recovery programs. This partnership aims to improve patient outcomes through integrated robotics-assisted surgery and rehabilitation. The CORI Surgical System will also launch in Europe after its successful introduction in the U.S. in 2020.
Smith+Nephew (NYSE:SNN) announced a real-world study from Spain showing that their ALLEVYN LIFE Foam Dressings significantly reduced dressing change frequency by 47.1% and weekly dressing costs by 58.7%. Conducted across 24 primary care centers and six nursing homes, the study included 94 patients with a median age of over 70. Healthcare professionals noted improved patient satisfaction and treatment experiences despite fewer nursing visits, showcasing ALLEVYN LIFE's effective exudate management and cost efficiency in wound care.
Smith+Nephew (LSE:SN, NYSE:SNN) announced a new publication highlighting that its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) reduces surgical site infections (SSIs) by 63%, seroma by 77%, and dehiscence by 30%. The systematic review covered 29 studies with 5,614 patients, demonstrating the therapy's efficiency across various surgical specialties. The PICO sNPWT also decreases hospital stay length by nearly 2 days, potentially benefiting healthcare systems significantly. This evidence supports PICO therapy for preventing surgical complications effectively.